Oral Aripiprazole Open-Label Rollover Study
An Open- Label Rollover Study for Subjects With Schizophrenia Completing ABILIFY® (Aripiprazole) Clinical Study 31-03-241
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Kharkiv、乌克兰
- Study Site
-
Kiev、乌克兰
- Study Site
-
-
-
-
-
Moscow、俄罗斯联邦
- Study Site
-
Rostov-on-Don、俄罗斯联邦
- Study Site
-
St.Petersburg、俄罗斯联邦
- Study Site
-
Yaroslavl、俄罗斯联邦
- Study Site
-
-
-
-
-
Split、克罗地亚
- Study Site
-
-
-
-
-
Hyderabad、印度
- Study Site
-
Ludhiana、印度
- Study Site
-
Mumbai、印度
- Study Site
-
Tamilnadu、印度
- Study Site
-
-
-
-
-
Belgrade、塞尔维亚
- Study Site
-
Novi Sad、塞尔维亚
- Study Site
-
-
-
-
-
Buenos Aires、阿根廷
- Study Site
-
Mendoza、阿根廷
- Study Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Subjects with a confirmed Axis I Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of schizophrenia who must have completed Otsuka study 31-03-241 (NCT00102518) treatment of adolescent subjects with schizophrenia
Exclusion Criteria:
- Patients with a co-morbid serious, uncontrolled systemic illness
- Patients with a significant risk of committing suicide
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Oral Aripiprazole
Flexible dose of oral aripiprazole between 5 mg and 30 mg once daily for 72 months.
|
Flexible dose between 5 mg and 30 mg Aripiprazole tablets.
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths
大体时间：Up to 72 months
|
An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a subject. Change in clinical relevance (severity increased) was entered as a new AE in the current trial. Abnormal laboratory test findings were considered AEs if, in the opinion of the investigator, they represented an abnormal (clinically significant) change from baseline for that individual subject. An AE was considered serious if it was fatal; life-threatening; persistently or significantly disabling or incapacitating; required in-patient hospitalization or prolonged hospitalization; a congenital anomaly/birth defect; or other medically significant event that, based upon appropriate medical judgment, may have jeopardized the subject and may have required medical or surgical intervention. Additional information about Adverse Events can be found in the Adverse Event section. |
Up to 72 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Clinical Global Impression Severity of Illness (CGI-S) Score
大体时间：Baseline, Last Visit (Up to 72 Months)
|
The rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. A negative change from Baseline indicated improvement |
Baseline, Last Visit (Up to 72 Months)
|
|
Number of Participants With Clinical Significant Laboratory Tests
大体时间：Baseline, Up to 72 Months
|
Blood was collected for Fasting clinical laboratory tests (serum chemistry and hematology) at Baseline, Months 12, 24, 36, 48, 60, and 72 and were analyzed at a central laboratory. Clinically significant values are defined as the following: Bilirubin, total ≥ 2.0 mg/dL. Creatine phosphokinase > 500 U/L for participants 13-17 years or 3 times the upper limit of normal for participants ≥ 18 years [Reference Range (0 to 190 IU/L (females) and 0 to 235 IU/L (males)]. Eosinophils ≥ 10 %. Hematocrit < 30 % for participants 13-17 years old or ≥ 18 year old participants female ≤ 32 % and a 3 point decrease from baseline or male ≤ 37 % and a 3 point decrease from baseline. Hemoglobin female ≤ 9.5 g/dL or male ≤ 11.5 g/dL. Prolactin > 1 times the upper limit of normal [Reference range: 2 to 18 ng/mL (males) and 3 to 30 ng/mL (females)]. |
Baseline, Up to 72 Months
|
|
Number of Participants With Clinically Significant Heart Rate
大体时间：Baseline, Up to 72 months
|
Heart rate was measured at Baseline and at each visit supine (lying on the back) and standing.
A heart rate increase is an increase of ≥ 15 beats per minute (bpm) compared to Baseline.
A heart rate decrease is a decrease of ≥ 15 bpm compared to Baseline.
|
Baseline, Up to 72 months
|
|
Number of Participants With Clinically Significant Blood Pressure
大体时间：Baseline, Up to 72 months
|
Systolic and Diastolic blood pressure was measured at Baseline and at all visits supine (lying on the back) and standing. Systolic increase was an increase of ≥ 20 mm Hg compared to Baseline and systolic decrease was a decrease of ≥ 20 mm Hg compared to Baseline. A diastolic increase was an increase of ≥ 15 mm Hg compared to Baseline and a diastolic decrease was a decrease of ≥ 15 mm Hg compared to Baseline. |
Baseline, Up to 72 months
|
|
Number of Participants With Clinically Abnormal Changes in Electrocardiograms (ECGs) Evaluations
大体时间：Baseline, Up to 72 months
|
A 12-lead ECG was recorded at Baseline, Months 6, 12, 24, 36, 48, 60 and 72. Three readings taken 5 minutes were read by a central ECG reading service and averaged. Clinically significant ECGs were defined as: Sinus Bradycardia: ≤ 50 beats per minute (bpm), decrease of ≥ 15 bpm from Baseline. Supraventricular premature beat: ≥ 2 per 10 seconds, increase from Baseline. Ventricular premature beat: ≥ 1 per 10 seconds, increase from Baseline. Right bundle branch block: present. Other intraventricular block: QRS ≥ 0.10 seconds for age 13-17 years or QRS ≥ 0.11 seconds for age ≥ 18 years, an increase of ≥ 0.02 seconds from Baseline. Symmetrical T-wave inversion: present. QTcB (QT interval corrected Bazett's formula), QTcF (QT interval corrected Fridericia's formula), QTcN (QT corrected FDA Neuropharmacology Division formula), QTcE (QT corrected fractional exponent correction method: ≥ 420 msec for age 13-17 years or ≥ 450 msec for age ≥ 18 years, ≥ 10 % increase from Baseline. |
Baseline, Up to 72 months
|
|
Number of Participants Showing Significant Weight Gain or Loss
大体时间：Baseline, Up to 72 months
|
Weight was measured at Baseline, Months 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, and 72.
A clinically significant weight gain was defined as a ≥ 7 % increase from Baseline.
A clinically significant Weight loss was defined as a ≥ 7% decrease from Baseline.
|
Baseline, Up to 72 months
|
|
Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS)
大体时间：Baseline, Up to 72 months
|
The C-SSRS consisted of a baseline evaluation (completed at the first scheduled visit upon approval of protocol Amendment 3) that assessed the lifetime experience of the participant with suicide events and suicidal ideation and a post-baseline evaluation at each visit that focused on suicidality since the last trial visit.
Some questions are yes/no and some are on a scale of 1 (low severity) to 5 (high severity).
The number of participants experiencing suicidal ideation or suicidal behavior is reported.
|
Baseline, Up to 72 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.